K Kast Selected Research

Anthracyclines

12/2014

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

K Kast Research Topics

Disease

4	Breast Neoplasms (Breast Cancer) 06/2022 - 12/2014
2	Neoplasms (Cancer) 01/2024 - 12/2014
2	Ovarian Neoplasms (Ovarian Cancer) 07/2021 - 01/2020
1	Endometrial Neoplasms (Endometrial Cancer) 07/2021
1	Chronic Disease (Chronic Diseases) 07/2021
1	Triple Negative Breast Neoplasms 12/2014

Drug/Important Bio-Agent (IBA)

2	Oral ContraceptivesIBA 06/2022 - 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2024
1	Estrogens (Estrogen)FDA Link 07/2021
1	Bevacizumab (Avastin)FDA Link 12/2014
1	Everolimus FDA Link 12/2014
1	Docetaxel (Taxotere)FDA Link 12/2014
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2014
1	Epirubicin (Ellence)FDA LinkGeneric 12/2014
1	AnthracyclinesIBA 12/2014
1	taxaneIBA 12/2014

Therapy/Procedure

1	Hormone Replacement Therapy (Therapy, Hormone Replacement) 07/2021
1	Salpingo-oophorectomy 07/2021
1	Contraception (Birth Control) 01/2020
1	Neoadjuvant Therapy 12/2014